Home » Posts tagged 'shareholders' (Page 3)
Tag Archives: shareholders
Alan Green covers #PETS Pets at Home, #COIN Coinsilium & #KDNC Cadence Minerals on the Vox Markets podcast
Alan Green covers #PETS Pets at Home, #COIN Coinsilium & #KDNC Cadence Minerals on the Vox Markets podcast
Listen to the Podcast here
Cadence Minerals #KDNC – Result of Placing & Subscription and TVR
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.
THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT ITSELF CONSTITUTE AN OFFER FOR SALE OR SUBSCRIPTION OF ANY SECURITIES IN THE COMPANY. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES OF CADENCE MINERALS PLC IN ANY JURISDICTION IN WHICH ANY SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL.
Cadence Minerals Plc
(“Cadence Minerals”, “Cadence” or the “Company”)
Result of Placing & Subscription and Total Voting Rights
Cadence Minerals (AIM/AQX: KDNC; OTC: KDNCY) is pleased to announce that it has successfully raised gross proceeds of £4.1 million in an oversubscribed fundraising as announced yesterday (the “Placing”).
A total of 19,512,180 Placing Shares in the Company have been placed by WH Ireland Limited (“WH Ireland”) with new and existing investors at a price of 20.5 pence per share (the “Issue Price”).
In addition, the Company has secured a further £0.1 million via a direct subscription (the “Subscription”) of 487,805 shares at the Issue Price (the “Subscription Shares”).
The fundraise was significantly oversubscribed in both the Placing and Subscription and the Directors of the Company are delighted by the support from existing shareholders and new investors, including institutional investors.
Application will be made to the London Stock Exchange for the Placing Shares and Subscription Shares to be admitted to trading on AIM and to the AQSE Growth Market and it is anticipated that dealings in the Placing and Subscription Shares will commence on AIM at 8.00 a.m. on 10 February 2022 (“Admission”). The Placing and Subscription Shares will represent approximately 11.9 per cent. of the Company’s issued share capital following completion of the Placing (“Enlarged Share Capital”). The Issue Price represents a discount of approximately 17.1 per cent. to the closing mid-market price of Cadence’s existing ordinary shares of 24.75 pence on 1 February 2022 (being the last business day prior to the announcement of the Placing yesterday).
Following Admission, the Company’s issued and fully paid share capital will consist of 168,049,083 Ordinary Shares, all of which carry one voting right per share. The Company does not hold any Ordinary Shares in treasury. The figure of 168,049,083 Ordinary Shares may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority.
Capitalised terms used but not defined in this announcement have the meanings given to them in the Company’s announcement released earlier today in respect of the Placing unless the context provides otherwise.
Enquiries:
Cadence Minerals plc |
+44 (0) 207 440 0647 |
Andrew Suckling |
|
Kiran Morzaria |
|
|
|
WH Ireland Limited (NOMAD & Broker) |
+44 (0) 207 220 1666 |
James Joyce / Darshan Patel |
|
Harry Ansell / Daniel Bristowe |
|
|
|
Novum Securities Limited (Joint Broker) |
+44 (0) 207 399 9400 |
Jon Belliss |
|
This announcement includes inside information as defined in Article 7 of the UK version of Market Abuse Regulation No. 596/2014 as it forms part of UK law as retained EU law as defined in, and by virtue of, the European Union (Withdrawal) Act 2018, as amended, and is disclosed in accordance with the Company’s obligations under Article 17 of those Regulations.
#ECHO Echo Energy – Total Voting Rights
Echo Energy, the Latin American focused full cycle energy company announces, in accordance with the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules, the following information as at 31 January 2022:
Class of share |
Total number of shares |
Number of voting rights per share |
Total number of voting rights per class of share
|
Ordinary shares of 0.25p each (“Ordinary Shares”)
|
1,452,491,345
|
1 |
1,452,491,345
|
No Ordinary Shares are held in treasury.
The above figure for total number of Ordinary Shares may be used by shareholders as the denominator for the calculations by which they determine if they are required to notify their interest in, or change to their interest in, the Company under the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.
#POLB Poolbeg Pharma – Confirmation of vaccine platform licence execution
31 January, 2022 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical stage infectious disease pharmaceutical company with a capital light clinical model, confirms that it has signed the licence to AnaBio Technologies’ (‘AnaBio’) microencapsulation and nanoencapsulation technologies to develop an oral vaccine delivery platform.
This follows the binding term sheet announced on 16 December 2021. This licence provides Poolbeg with exclusive access to AnaBio’s microencapsulation and nanoencapsulation technologies for use in the development and commercialisation of vaccines. Combined with the Company’s expertise in infectious diseases and vaccine development, Poolbeg will use this technology as a platform to complement its existing and growing pipeline of assets by developing oral vaccines for multiple disease indications.
Oral vaccines have been used successfully, but in a limited way, for decades, such as in the prevention of polio and typhoid. Broadening the range of diseases with oral vaccines available is beneficial as they can provide enhanced benefits by delivering antigens to specific areas of the gut, triggering the development of ‘mucosal immunity’ which prevents pathogens from infecting the body. The COVID-19 pandemic has accelerated demand for innovation in the development of vaccines, and oral vaccines offer many advantages having improved vaccine stability profiles, easier global distribution and administration as well as tackling the issue of needle-phobia.
This is the latest in several licence agreements that Poolbeg has completed since its IPO in July 2021, demonstrating delivery against commitments made at the time of listing. The Company’s pipeline of assets continues to expand and is increasing in diversity with the addition of this innovative oral vaccine delivery platform. This latest licencing agreement follows swiftly on the back of a series of other recently announced potentially ground-breaking infectious disease asset deals. This includes the first-in-class, intranasally administered, RNA-based immunotherapy for respiratory virus infections announced on 17 January 2022 (POLB 002). In December 2021 the Company announced that it had successful signed an option agreement to licence an intramuscular Melioidosis vaccine (POLB 003). Melioidosis is a disease which presents a dangerous and underappreciated threat to human health which currently has no approved vaccine and a very high mortality rate and in addition, concerns are growing around global warming contributing to the spread of the disease to traditionally non-tropical areas. These new assets are in addition to the Company’s lead programme, POLB 001, a treatment for severe influenza. Post-pandemic the global community recognises the importance of vaccines and treatments against infectious disease and governments are hugely increasing their investment into influenza pandemic preparedness.
Jeremy Skillington, PhD, CEO of Poolbeg Pharma, said:
“Vaccine uptake is a critical factor in the effectiveness of combating communicable infectious diseases, something that the COVID-19 pandemic has shown in recent months. Oral vaccines bring significant benefits both in terms of the logistics required to distribute and administer them, but also in how the body responds through creating mucosal immunity in the gut and acting as a barrier to the infection.
“This licencing deal with AnaBio and the access to its advanced micro- and nano-encapsulation technologies will enable Poolbeg to develop an oral vaccine delivery platform from which to complement an already diverse pipeline of treatments and vaccines against infectious diseases.”
Aidan Fitzsimons, PhD, CEO of, AnaBio Technologies, said:
“This is a really exciting opportunity to apply AnaBio’s patented micro-encapsulation technology, which has been shown to facilitate absorption of Active Pharmaceutical Ingredients (API’s) through the gut, in the development of an oral vaccine. Micro-encapsulation is a process which involves coating microscopic particles of an API with a protective layer enabling the API to travel safely through the digestive system, and be absorbed across the gut in a bioavailable form. Combining AnaBio’s proven micro-encapsulation technology and Poolbeg’s vaccine and immunology expertise puts us both in a great position to deliver a genuine breakthrough innovation in oral vaccine development.”
– Ends –
Enquiries
Poolbeg Pharma Plc
Jeremy Skillington, CEO Ian O’Connell, CFO
|
+44 (0) 207 183 1499 |
finnCap Ltd (Nominated Adviser & Joint Broker)
Geoff Nash, James Thompson, Charlie Beeson
|
+44 (0) 20 7220 0500 |
Arden Partners PLC (Joint Broker)
John Lewellyn-Lloyd, Louisa Waddell
|
+44 (0) 207 614 5900 |
J&E Davy (Joint Broker)
Anthony Farrell, Niall Gilchrist
|
+353 (0) 1 679 6363 |
Instinctif Partners
Melanie Toyne Sewell, Rozi Morris, Tim Field |
+44 (0) 20 7457 2020 |
#MSMN Mosman Oil and Gas – Result of Annual General Meeting
Mosman Oil and Gas Limited (AIM: MSMN) the oil exploration, development, and production company, announces that the 2021 AGM was held in Sydney earlier today. The meeting was held in accordance with COVID protocols currently in place in Sydney, and Australia.
Resolution 1, the re-election of Mr. JW Barr as a Director, was placed before shareholders. The following proxies were received:
For |
511,967,495 |
78.44% |
Against |
138,546,916 |
21.23% |
Abstain |
2,134,772 |
0.33% |
The Resolution was passed on a show of hands.
Resolution 2, in respect of a potential share consolidation, was withdrawn as previously announced.
Previously the Company had sought questions from shareholders. A summary of the questions and answers will be published on the Company’s website.
Enquiries:
Mosman Oil & Gas Limited John W Barr, Executive Chairman Andy Carroll, Technical Director |
NOMAD and Joint Broker SP Angel Corporate Finance LLP Stuart Gledhill / Richard Hail / Adam Cowl +44 (0) 20 3470 0470 |
Alma PR Justine James / Joe Pederzolli +44 (0) 20 3405 0205 +44 (0) 7525 324431 |
Joint Broker Monecor (London) Ltd trading as ETX Capital Thomas Smith 020 7392 1432 |
#POLB Poolbeg Pharma – Poolbeg Pharma licences first-in-class broad spectrum RNA-based immunotherapy for respiratory virus infections from the University of Warwick
17 January, 2022- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has in-licenced a novel, first-in-class RNA-based immunotherapy for respiratory virus infections developed at the University of Warwick.
Poolbeg has secured an exclusive licence to this dual antiviral prophylactic and therapeutic candidate, which is at a late-pre-clinical development stage. In vivo data confirms that this immunotherapy asset targets pan-respiratory virus infections, which could include influenza, respiratory syncytial virus (RSV), SARS-CoV-2 and others.
The candidate, which will be developed by Poolbeg as POLB 002, was developed at the University of Warwick and derived from twenty years of research with world class virologists, Professor Andrew Easton and Professor Nigel Dimmock.
Administered intra-nasally, this RNA-based immunotherapy works by triggering nasal cells into an antiviral state to protect from the infecting virus. Simultaneously, it blocks the cells from making more virus by directly preventing its replication. Both modes of action combined can reduce infectious viral loads and improve disease symptoms. As a nasally administered and rapidly effective prophylactic antiviral candidate, it could potentially provide an effective solution for protecting at risk patient populations (e.g. the elderly, COPD patients, and asthmatics).
Respiratory virus infections are considered a top five global killer resulting in more than three million annual deaths worldwide. There is a significant unmet need for improved respiratory virus infection therapies and the current available treatments, vaccines and antiviral drugs, are typically pathogen specific. Consequently, 85% of illnesses caused by non-influenza viruses cannot be adequately treated and the emergence of resistance is also a major concern.
Jeremy Skillington, PhD, CEO of Poolbeg Pharma, said: “This dual action immunotherapy developed by the team at University of Warwick is a really exciting technology in the field of respiratory virus disease treatments. The data shows it to rapidly reduce viral load and also prevent the likelihood of virus resistance.
“It will be an excellent addition to our growing pipeline of assets and we plan to move rapidly towards human proof-of-concept studies using our capital light clinical model. We look forward to updating the market as POLB 002 progresses through the clinic with the ultimate aim of partnering it with Big Pharma.”
Professor Andrew Easton, from the School of Life Sciences at the University of Warwick, said: “Currently most respiratory virus infections cannot be treated despite being responsible for millions of deaths each year. This is a very exciting new approach with great potential. We are delighted to be developing it alongside the Poolbeg Pharma team, with their extensive knowledge and experience in the sector.”
– Ends –
Enquiries
Poolbeg Pharma Plc
Jeremy Skillington, CEO Ian O’Connell, CFO
|
+353 (0) 1 644 0007 |
finnCap Ltd (Nominated Adviser & Joint Broker)
Geoff Nash, James Thompson, Charlie Beeson
|
+44 (0) 20 7220 0500 |
Arden Partners PLC (Joint Broker)
John Lewellyn-Lloyd, Louisa Waddell
|
+44 (0) 207 614 5900 |
J&E Davy (Joint Broker)
Anthony Farrell, Niall Gilchrist
|
+353 (0) 1 679 6363 |
Instinctif Partners
Melanie Toyne Sewell, Rozi Morris, Tim Field |
+44 (0) 20 7457 2020 |
University of Warwick +44 (0) 7920 531 221
|
#ECHO Echo Energy – Directorate Changes
Echo Energy, the Latin American focused full cycle energy company, is pleased to announce the appointment of Christian Yates as an independent non-executive director, with effect from 17 January 2022.
Christian is Chairman of Gresham House Renewable Energy VCT 2 plc, one of two listed investment companies he co-founded in 2010. He has been investing in, advising on and promoting investments in renewable energy since 2009.
Following eight years in the British Army, Christian began his career in fund management in 1988. He has worked for several investment houses holding senior positions at Bear Stearns Asset Management where he was CEO International, Julius Baer Investments as CEO London, Chase Asset Management as MD EMEA and Lazard Asset Management.
Since 2012, Christian has combined being an entrepreneur and consultant with being a non-executive director, with significant experience across sectors including renewable energy (including wind, waste to energy and BESS), real estate, hospitality, fund management and wealth management where until October 2020 he was Chairman of the Bowmore Wealth Group.
The Company also announces that Gavin Graham, a non-executive director of the Company, will be stepping down as a director of the Company concurrently with Christian’s appointment in order to maintain a fit for purpose board composition and size.
James Parsons, Non-executive Chairman, commented:
“I am delighted to welcome Christian to the Board. His deep background across the renewable energy space is a critical enabler for our energy transition in Latin America and will add a vital and relevant dimension to our thinking. We will benefit hugely from Christian’s wealth of experience throughout the energy arena and I look forward to working with him.
I am also extremely grateful to Gavin for his support at Echo over the years, his contributions to our board discussions and I wish him all the best for his future endeavours.”
The directorships and partnerships currently held by Christian Yates and over the five years preceding the date of appointment are as follows:
Mr Christian James Kurt Yates , aged 59
|
|
Current directorships/partnerships | Previous directorships/partnerships |
Aura Sustainable Capital Investments Ltd
Away Birmingham Limited Away Cheltenham Limited Away Holdings Limited Away Storage Limited Away Storage Liverpool Limited CJK & RA Yates LLP Gresham House Renewable Energy VCT 2 plc New Radiation (2008) LLP Remount T/A Future for Heroes Ltd Weirs Drove Development Limited
|
127 Piccadilly Plc
Aura Renewables Infrastructure Trust plc Bowmore Asset Management Limited Bowmore Financial Planning Limited Bowmore Wealth Group Limited Canvenue Limited Cherif Barnes Developments Limited Cherif Hampton Row Holdco Ltd Cherif Investment Properties Ltd Hampton Row (Barnes) Management Limited Managed Storage Services (1) Ltd W4B (UK) Limited
|
Mr Yates was appointed as a director of W4B Bristol Limited on 27 April 2009. Liquidators were appointed to W4B Bristol Limited on 17 March 2015 and that company was dissolved on 12 April 2016. Unsecured creditors were paid a first and final dividend totalling £30,350, equating to 19.96 pence per GBP on unsecured claims of £152,048.
Christian Yates does not hold any ordinary shares in the Company and there are no further disclosures to be made pursuant to Schedule 2 paragraph (g) of the AIM Rules.
|